Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial

At median follow up of 35.7 months, addition of veliparib to carboplatin–paclitaxel resulted in improved progression-free survival in 513 patients with germline BRCA mutation-associated advanced breast cancer (14.5 vs 12.6 months; HR for progression or death = 0.71;


The Lancet Oncology